Biomarker | Serrated polyp, OR (95% CI)a | |||||
---|---|---|---|---|---|---|
Q1 (lowest) | Q2 | Q3 | Q4 (highest) | P for trend | Per 1-SDb | |
Estrone | ||||||
 No. of cases | 45 | 48 | 47 | 53 |  |  |
 Model 1 | 1 | 1.13 (0.74–1.71) | 1.11 (0.73–1.69) | 1.39 (0.92–2.11) | 0.33 | 1.07 (0.93–1.23) |
 Model 2 | 1 | 1.11 (0.72–1.69) | 1.05 (0.69–1.61) | 1.26 (0.79–1.99) | 0.74 | 1.03 (0.88–1.21) |
Total estradiol | ||||||
 No. of cases | 52 | 47 | 48 | 65 |  |  |
 Model 1 | 1 | 0.93 (0.62–1.39) | 0.96 (0.64–1.43) | 1.51 (1.04–2.19) | 0.02 | 1.24 (1.04–1.47) |
 Model 2 | 1 | 0.90 (0.59–1.35) | 0.86 (0.57–1.30) | 1.30 (0.85–1.99) | 0.15 | 1.17 (0.95–1.44) |
Free estradiol | ||||||
 No. of cases | 47 | 38 | 54 | 55 |  |  |
 Model 1 | 1 | 0.77 (0.50–1.19) | 1.20 (0.81–1.80) | 1.40 (0.94–2.10) | 0.01 | 1.28 (1.07–1.52) |
 Model 2 | 1 | 0.69 (0.44–1.08) | 1.09 (0.72–1.65) | 1.14 (0.70–1.86) | 0.13 | 1.18 (0.95–1.46) |
Total testosterone | ||||||
 No. of cases | 96 | 96 | 88 | 89 |  |  |
 Model 1 | 1 | 1.02 (0.76–1.36) | 0.90 (0.67–1.21) | 0.96 (0.71–1.29) | 0.66 | 0.98 (0.88–1.09) |
 Model 2 | 1 | 1.01 (0.76–1.36) | 0.86 (0.64–1.16) | 0.88 (0.65–1.20) | 0.32 | 0.95 (0.85–1.05) |
Free testosterone | ||||||
 No. of cases | 75 | 86 | 93 | 92 |  |  |
 Model 1 | 1 | 1.17 (0.85–1.60) | 1.34 (0.99–1.83) | 1.47 (1.08–2.01) | 0.003 | 1.19 (1.06–1.34) |
 Model 2 | 1 | 1.04 (0.76–1.43) | 1.05 (0.76–1.45) | 1.03 (0.73–1.44) | 0.49 | 1.05 (0.92–1.19) |
SHBG | ||||||
 No. of cases | 117 | 102 | 78 | 81 |  |  |
 Model 1 | 1 | 0.79 (0.60–1.04) | 0.59 (0.44–0.79) | 0.55 (0.41–0.73) | <.0001 | 0.79 (0.71–0.87) |
 Model 2 | 1 | 0.89 (0.67–1.18) | 0.70 (0.51–0.96) | 0.72 (0.51–1.02) | 0.01 | 0.86 (0.76–0.97) |
Total estradiol/total testosterone | ||||||
 No. of cases | 48 | 45 | 46 | 59 |  |  |
 Model 1 | 1 | 0.91 (0.60–1.38) | 0.95 (0.63–1.43) | 1.35 (0.91–2.01) | 0.08 | 1.16 (0.98–1.38) |
 Model 2 | 1 | 0.86 (0.56–1.32) | 0.86 (0.56–1.32) | 1.23 (0.78–1.92) | 0.24 | 1.13 (0.92–1.38) |